Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis (COLETTE)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Status Epilepticus
Dysimmune Encephalopathy

Treatments

Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)

Study type

Interventional

Funder types

Other

Identifiers

NCT04421846
APHP200306
2020-A00053-36 (Other Identifier)

Details and patient eligibility

About

COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.

Full description

Epilepsy is one of the most common neurological condition which concerns around 50 million people worldwide. Epilepsy is characterized by a lasting predisposition to generate seizures. Epilepsy can present as heterogenous set of clinical symptoms and is related to extremely varied etiologies. Some epilepsies are triggered by antineuronal autoantibodies and/or complicated by a status epilepticus. These conditions may induce brain atrophy, and severe neurological sequels. The severity of these epilepsies requires significant efforts to (i) identify new therapeutic strategies able to control the evolution of dysimmune encephalitis and refractory status epilepticus, (ii) to identify their etiologies and (iii) to propose neuroprotective strategies. Therefore, the investigators will organize a collection of biological samples (blood, cerebrospinal fluid, post-mortem brain tissues) and paraclinical data (electroencephalogram, evoked potential, CT, MRI) in patients with severe epilepsies, whether or not associated with autoantibodies, and/or evolving into status epilepticus. This study should bring new insights allowing to better understand mechanisms that trigger the emergence of an epileptic brain (epileptogenesis) through : (i) the identification and characterization of new pathophysiological pathways involving autoimmunity directed against the cerebral cortex and associated with severe epilepsy (ii) the identification and characterization of pathophysiological pathways participating in the excitotoxicity observed in status epilepticus.

Enrollment

400 estimated patients

Sex

All

Ages

2+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Group 1:

  • Patients aged 2 years or above, with status epilepticus.
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not

Group 2:

  • Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not

Group 3:

  • Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not

Exclusion criteria

Group 1:

  • Women with known or clinically detected pregnancy.
  • Patient deprived of liberty
  • Patients with known neurodegenerative disease.

Group 2:

  • Women with known or clinically detected pregnancy.
  • Patient deprived of liberty
  • Patients have been already treated by corticoids or IgIV.

Group 3:

  • Women with known or clinically detected pregnancy.
  • Patient deprived of liberty.
  • Patients with status epilepticus.
  • Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

400 participants in 3 patient groups

Group 1 : Status epilepticus
Other group
Treatment:
Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Group 2 : Dysimmune encephalitis
Other group
Treatment:
Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Group 3 : Control patients
Other group
Treatment:
Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)

Trial contacts and locations

1

Loading...

Central trial contact

Vincent NAVARRO, Pr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems